Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 17Terminated 9Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 129Other hematologic neoplasm 34Myeloid 3Sarcoma 2Plasma cell 1Other solid neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Dexamethasone 130Lenalidomide 82daratumumab 60Bortezomib 56carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 31isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15fludarabine 13Melphalan 13iberdomide 11elotuzumab 11selinexor 10fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Rituximab × Plasma cell × Clear all
NCT01810588 2025-09-02

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Weill Medical College of Cornell University

Phase 2 Active not recruiting
270 enrolled 13 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡